Related Experiment Video
Updated: Jun 26, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
HDAC inhibitors in models of inflammation-related tumorigenesis
Rainer Glauben1, Elena Sonnenberg, Martin Zeitz
1Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Medical Department I, Berlin, Germany.
Abstract:
Histone deacetylase (HDAC) inhibitors have been described in detail for their anti-proliferative potency. Recently, an anti-inflammatory property was characterized in vitro and in vivo. This dual efficacy of HDAC inhibitors is highly attractive, since chronic inflammations such as ulcerative colitis are associated with an increased risk of developing carcinomas. Additionally, in models of colitis and inflammation-induced tumorigenesis inflammation as well as tumor development was significantly inhibited by HDAC inhibitor treatment. The mechanisms involved reach beyond the simple regulation of histone acetylation and deacetylation. The currently known key target structures and mechanisms mediating this dual effect will be discussed in this review.
Related Concept Videos
Chronic Inflammation: Introduction
Mutagenicity and Carcinogenicity
Inflammatory Bowel Disease III: Crohn's Disease
Abnormal Proliferation
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inhibition of Cdk Activity
